ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Industry News & Regulatory Approvals

FLAURA-2 Results Lead to Approval of Osimertinib Plus Chemotherapy in European Union, Japan

Erin Jungmeyer
on: July 23, 2024In: Industry News & Regulatory Approvals
FLAURA-2 Results Lead to Approval of Osimertinib Plus Chemotherapy in European Union, Japan

In other recent regulatory news, Health Canada authorized amivantamab in combination with carboplatin and pemetrexed for patients with non-small cell lung cancer with EGFR Exon 20 insertion mutations. Read more


Recently Reported Evidence Leads to Approvals for Alectinib, Osimertinib

Erin Jungmeyer
on: June 25, 2024In: Industry News & Regulatory Approvals
Recently Reported Evidence Leads to Approvals for Alectinib, Osimertinib

The European Commission has approved adjuvant alectinib for ALK+ early-stage NSCLC while the US FDA has granted priority review for osimertinib for unresectable stage III EGFR+ NSCLC. Read more

US FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-stage Small Cell Lung Cancer

Erin Jungmeyer
on: June 11, 2024In: Industry News & Regulatory Approvals
US FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-stage Small Cell Lung Cancer

The first-in-class immunotherapy offers a new option for SCLC patients with disease progression on or after platinum-based chemotherapy. Read more

European Commission OKs Tislelizumab for NSCLC

Erin Jungmeyer
on: May 21, 2024In: Industry News & Regulatory Approvals
European Commission OKs Tislelizumab for NSCLC

In other regulatory news, the US FDA recently granted a Breakthrough Therapy Designation for sunvozertinib for first-line treatment of advanced non-small cell lung cancer with EGFR Exon 20 Insertion mutations. Read more

ALINA Trial Leads to New Treatment Option for Early-Stage ALK+ NSCLC

Erin Jungmeyer
on: May 07, 2024In: Industry News & Regulatory Approvals
ALINA Trial Leads to New Treatment Option for Early-Stage ALK+ NSCLC

The US approved alectinib as adjuvant treatment based on a significant DFS benefit compared to chemotherapy. Read more

Stark Contrast in Recent Tobacco Control Laws Worldwide

Erin Jungmeyer
on: May 07, 2024In: Industry News & Regulatory Approvals, Tobacco Control & Smoking Cessation
Stark Contrast in Recent Tobacco Control Laws Worldwide

The UK recently moved to ban smoking for individuals born after 2009 while the US delayed implementation of a ban on menthol cigarettes—again. Read more

Regulatory News for April 24, 2024

Erin Jungmeyer
on: April 23, 2024In: Industry News & Regulatory Approvals
Regulatory News for April 24, 2024

US FDA grants accelerated approval of HER2-targeting antibody drug conjugate; China accepts supplemental new drug application for savolitinib. Read more

US Food and Drug Administration Accepts New Drug Application for Ensartinib

Erin Jungmeyer
on: April 09, 2024In: Industry News & Regulatory Approvals
US Food and Drug Administration Accepts New Drug Application for Ensartinib

The filing was based on results from a global phase III study designed to compare the ALK inhibitor to crizotinib in the first-line treatment of ALK-positive NSCLC. Read more

Regulating Artificial Intelligence

Erin Jungmeyer
on: March 26, 2024In: Evolving Standards of Care, Industry News & Regulatory Approvals
Regulating Artificial Intelligence

The US FDA’s Dr. Harpreet Singh talks with ILCN about what the increasing use of AI means for the agency as it works to ensure drugs and devices are safe and effective. Read more

US FDA Grants Breakthrough Therapy Designation for Novel TKI Targeting HER2, EGFR

Erin Jungmeyer
on: March 26, 2024In: Industry News & Regulatory Approvals
US FDA Grants Breakthrough Therapy Designation for Novel TKI Targeting HER2, EGFR

The move was supported by preliminary evidence from a phase I, first-in-human study in patients with advanced NSCLC. Read more

‹123456›»

SEARCH ILCN

Archives

PROVIDER RESOURCES

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED


COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy